Archive notice: This video was recorded during the COVID-19 pandemic. It is retained for historical context; patients should follow current guidance from their treating team.
Video transcript
Read the discussion
COVID-19 has played a havoc with the lives of cancer patients. Because often because of the COVID-19 pandemic scare patients are not coming to the hospital for their therapies whether it is chemotherapy or radio ligand therapy. Now specifically for Lutetium PSMA Therapy the entire philosophy or the science behind giving multiple fractionated doses of Lu PSMA at intervals of about 6-8 weeks, is to give repeated dosage of insult to the tumour, now if these doses are not given at frequent intervals or at the designated intervals, the tumour cells begin to find ways of becoming refractory to this tumour and that really damages the response rate of Lu PSMA to this therapy. So unless these therapies are given in the adequate dosages at adequate intervals the overall response rate are the overall outcomes would be much poorer.
Note: The content provided on this video is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Medical information notice: This video is educational and does not replace an individual consultation. Treatment suitability depends on current imaging, pathology, prior therapy, organ function and multidisciplinary clinical review.